Meeting Coverage – TOP DAILY NEWS

Dec292024 by adminNo Comments

Incorporating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

Meeting Coverage > > ASH Expert Roundtable: Multiple Myeloma-- Experts weigh the function of MRD in customizing treatment however care versus early modifications by Greg Laub, Director, Video, MedPage Today December 28, 2024 At the American Society of Hematology yearly conference, a roundtable conversation highlighted the progressing function of very little recurring illness (MRD) as a treatment endpoint in several myeloma, exploring its ramifications for treatment escalation, de-escalation, and discontinuation. MedPage Today united 3 skilled leaders in the field: Moderator Joseph Mikhael, MD, is signed up with by Amrita Krish...

Nov222024 by adminNo Comments

‘A Watershed Moment’: GLP-1 Drug Succeeds in Late-Stage MASH Trial

Health and Mediacal

Meeting Coverage > > AASLD-- First favorable stage III research study for a GLP-1 agonist in persistent liver illness by Mike Bassett, Staff Writer, MedPage Today November 20, 2024 Semaglutide (Wegovy) enhanced liver fibrosis in clients with metabolic dysfunction-associated steatohepatitis (MASH) and resulted in higher rates of MASH resolution, an interim analysis of a stage III trial revealed. In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist led to greater week-72 rates of steatohepatitis resolution without getting worse of liver fibrosis (63% vs 34% with placebo) and enhancement in liver fibrosis without in...

Nov192024 by adminNo Comments

Huge Blow to Anticoagulation Strategy Against Afib-Related Cognition Problems

Health and Mediacal

Meeting Coverage > > AHA-- Microemboli now questioned as motorist of cognitive disability in atrial fibrillation by Nicole Lou, Senior Staff Writer, MedPage Today November 17, 2024 CHICAGO-- Researchers stopped working to avoid cognitive disability in individuals with existing atrial fibrillation (Afib) by going the path of anticoagulation to alleviate subclinical brain infarcts, according to the BRAIN-AF trial. Stopped early for futility, BRAIN-AF recommended a comparable danger of cognitive decrease, stroke, or short-term ischemic attack (TIA) whether Afib clients with a low danger of stroke-- a group without an existing indicator for antico...

Nov62024 by adminNo Comments

Alzheimer’s Diagnosis Takes More Than Biomarkers, Working Group Says

Health and Mediacal

Meeting Coverage > > CTAD-- Competing meaning that consists of cognitive signs proposed by Judy George, Deputy Managing Editor, MedPage Today November 4, 2024 A meaning of Alzheimer's illness-- one that needs unbiased cognitive deficits in addition to brain amyloid for Alzheimer's to be detected-- was proposed by the International Working Group (IWG). The proposition existed at the Clinical Trials on Alzheimer's Disease (CTAD) yearly conference in Madrid and released concurrently in JAMA Neurology It's an extension of earlier positions by the IWG that for medical usage, cognitive signs should exist and a meaning of Alzheimer's rooted just in b...

Sep212024 by adminNo Comments

Blood Markers Help Predict MS Disease Progression

Health and Mediacal

Meeting Coverage > > ECTRIMS-- Patients with high NfL at illness beginning might take advantage of high-efficacy treatments by Judy George, Deputy Managing Editor, MedPage Today September 19, 2024 Blood biomarkers at illness beginning might assist anticipate relapse-associated intensifying and development independent of regression activity (PIRA) in several sclerosis (MS), an observational research study recommended. Serum levels of neurofilament light (NfL), a marker of axonal injury, forecasted both relapse-associated worsening and PIRA, reported Enric Monreal, MD, PhD, of the Hospital Universitario Ramón y Cajal in Madrid, who provided the ...